No Detail Found!

Pharmacological innovations in psychiatric treatment: exploring novel therapeutic targets

Author(s)
Mohammad Ali Dr. Akbar Niazi Teaching Hospital, Islamabad, Pakistan.
Urbah Viqar Dr. Akbar Niazi Teaching Hospital, Islamabad, Pakistan.
Abstract
Psychiatric disorders pose frequent treatment challenges thus exploring new treatment modalities is always desirable by the experts in the field. Possible treatment options include medications that can alter or target the glutamatergic system, immunologic system, and/ or neuroinflammatory pathways. The eficacy of such systems has been demonstrated in preclinical and clinical trials, mainly in the enhancement of symptoms related to mental disorders. However, questions arise like: Is it feasible to develop the target? Do the emiting pole and the receiving pole indicate that the treatment is the best one? On what basis should the patients be grouped? Assessing such pathogenic mechanisms concerning novel targets will enable the identifcation of the course toward personalized and patient-tailored medication for a variety of psychiatric ailments. The findings of this narrative literature review may shed light on the new potential therapeutic targets for psychiatric diseases, that may be utilized for beetr treatment outcomes in the mental healthcare system.
Publication Details
Page(s) 119-122
Published Journal: Biomedica, Volume: 40, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
Neuroinflammation, Psychiatric illnesses, glutamatergic neurotransmission, glutamatergic system
References
Vollenweider FX,Preller KH .2020 .Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosc, 21(11) : 611-24.
Nutt D,Erritzoe D,Carhart-Harris R .2020 .Psychedelic psychiatry's brave new world. Cell, 03(1) : 24-8.
Karthik S,Sharma LP,Narayanaswamy JC .2020 .Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives. Neuropsychiatr Dis Treat, 16 : 1003-13.
Paulus MP,Thompson WK,Liu Q,He H,Yang J,Feng X,Zhao F,Lyu J,McClure-Begley TD,Roth BL,Rhee TG,Olfson M,Nierenberg AA,Wilkinson ST,Sartori SB,Singewald N.,García-Gaytán AC,Hernández-Abrego A,Díaz-Muñoz M,Méndez I. .2022 .Glutamatergic system components as potential biomarkers and therapeutic targets in cancer in non-neural organs. Front Endocrinol, 13(8) : 1029210-15.
Baldessarini RJ,Tondo L,Vázquez GH .2019 .Pharmacological treatment of adult bipolar disorder. J Mol Psychiatry, 24(2) : 198-217.
McIntyre RS .2022 .Rapid-acting antidepressants in psychiatry: psychedelics, episodic treatments, innovation, and clarion call for methodologic rigor in drug development. Expert Opin Drug Saf, 21(6) : 715-6.
Staudt MD,Herring EZ,Gao K,Miller JP,Sweet JA .2019 .Evolution in the treatment of psychiatric disorders: from psychosurgery to psychopharmacology to neuromodulation. Front Neurosci, 13 : 108.
Correll CU,Cortese S,Croatto G,Monaco F,Krinitski D,Arrondo G .2021 .Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. Curr Psychiatry, 20(2) : 244-75.
Bousman CA,Bengesser SA,Aitchison KJ,Amare AT,Aschauer H,Baune BT .2021 .Review and consensus on pharmacogenomic testing in psychiatry. Int Pharmacopsychiatry, 54(01) : 5-17.
0

Citations

0

Downloads

35

Views